Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

BACKGROUND: To investigate the long-term efficacy and safety of empagliflozin monotherapy compared with placebo and sitagliptin in drug-naïve patients with type 2 diabetes mellitus. METHODS: Of 899 patients randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, placebo, or sitagliptin 100 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Roden, Michael, Merker, Ludwig, Christiansen, Anita Vedel, Roux, Flavien, Salsali, Afshin, Kim, Gabriel, Stella, Peter, Woerle, Hans J., Broedl, Uli C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690334/
https://www.ncbi.nlm.nih.gov/pubmed/26701110
http://dx.doi.org/10.1186/s12933-015-0314-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690334/
https://www.ncbi.nlm.nih.gov/pubmed/26701110
http://dx.doi.org/10.1186/s12933-015-0314-0

Ejemplares similares